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Morphine is the core of perioperative painmanagement. However, when it comes to cancer
surgery the possibility that this drug might affect tumor recurrence and metastasis has
raised concerns.The results of two recent retrospective clinical trials indicated that regional
anesthesia/analgesia might be beneﬁcial in prostate and breast cancer surgery. It was pro-
posed that morphine could be responsible for the higher recurrence and mortality rate
observed in the general anesthesia/opioid analgesia groups. Nevertheless, the results of
several other retrospective studies and one randomized prospective trial failed to conﬁrm
any advantage for regional anesthesia/analgesia over general anesthesia and opioid anal-
gesia. Moreover laboratory data on the effect of morphine on cancer are contradictory,
ranging from tumor-promoting to anti-tumor effects. Considering that surgical stress and
pain promote the recurrence and spread of cancer, choosing a proper analgesic strategy is
of high signiﬁcance.Although the question ofwhethermorphine causes any harm to cancer
patients remains unanswered, alternative analgesic regimens could be used concomitant
to or instead of morphine to limit its potential adverse effects.
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PERIOPERATIVE MORPHINE AND CANCER
There has been increased interest surrounding the possibility that
morphine should not be given perioperatively to cancer surgery
patients. This followed two retrospective clinical studies show-
ing that when regional (i.e., paravertebral or epidural) anesthe-
sia/analgesia was used in patients undergoing surgery for either
breast or prostate cancer, the rate of cancer recurrence, and/or
metastasis was signiﬁcantly lower than in patients undergoing
general anesthesiawith opioid analgesia. The follow-upperiodwas
2.5–4 years for the breast cancer and 2.8–12.8 years for the prostate
cancer study (Exadaktylos et al., 2006; Biki et al., 2008). One
of the hypotheses proposed to explain these results has involved
the opioid-sparing effect of regional anesthesia/analgesia, and the
assumption that morphine could be at least in part responsible for
the higher recurrence and mortality rate in the general anesthesia
groups, which received opioid analgesia.
Opioids are a major class of drugs in pain management and
morphine, as a potent agonist of the mu opioid receptor, is still the
drug of choice from this family (Paice, 2003). The concerns regard-
ing possible promoting effects of morphine on tumor growth and
metastasis mostly originated from the fact that opioids, includ-
ing morphine, have well-established immunosuppressive effects,
compromising cellular and humoral immune function and thus
host defense against malignancies (Ishikawa et al., 1993; Sacerdote
et al., 2000; Franchi et al., 2007). In addition,morphinehas recently
been reported to increase angiogenesis, thereby supporting tumor
growth in a breast cancer xenograft model in mice (Gupta et al.,
2002). Further fueling the debate, opioids were shown to transac-
tivate VEGF receptors, induce angiogenesis and promote vascular
permeability (Singleton et al., 2006, 2007), and activation of opi-
oid receptors was documented to enhance the proliferation and
invasion of lung cancer cells (Mathew et al., 2011).
Whilst these reports are convincing and the question of whether
morphine should be avoided in cancer surgery patients legiti-
mate, it must be kept in mind that the reported tumor-promoting
effect of opioids is balanced by their anti-tumor potential, doc-
umented at various levels (Table 1). Morphine has also been
shown to have direct anti-proliferative and pro-apoptotic effects
on different cancer cells (Maneckjee et al., 1990; Maneckjee
and Minna, 1994; Hatzoglou et al., 1996; Sueoka et al., 1998;
Tegeder et al., 2003; Zagon and Mclaughlin, 2003). Further-
more, several studies using endothelial cells (Balasubramanian
et al., 2001; Lam et al., 2008; Hsiao et al., 2009), chorioallan-
toic membranes (Pasi et al., 1991; Blebea et al., 2000), in vitro
capillary tube formation assay or implanted matrigel plugs (Lam
et al., 2008; Martin et al., 2010a,b), and in vivo tumor assays
(Koodie et al., 2010; Ustun et al., 2010), have demonstrated
angiostatic effects for morphine. However there is no clinical
study demonstrating the effect of morphine per se on tumor
growth, recurrence or metastasis. Postoperative pain manage-
ment is of high signiﬁcance especially in cancer patients. Fail-
ure to properly control postoperative pain, results in an exac-
erbated, and prolonged stress response, which increases the risk
of tumor spread in the postoperative period (Page et al., 2001).
The highly effective analgesic effect of opioids is suggested to
be beneﬁcial in reducing the surgical stress (Yeager and Colac-
chio, 1991; Page et al., 1993, 1998; Sasamura et al., 2002).
Therefore, if morphine analgesia is to be avoided in the peri-
operative period in cancer surgery patients, effective alternative
strategies should imperatively be adopted to effectively con-
trol postoperative pain. These include (i) the use of regional
anesthesia/analgesia, (ii) the co-administration with morphine
of a peripheral opioid antagonist, or (iii) alternate analgesic
interventions.
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Table 1 |The effect of morphine administration on tumor progression in animal models.
Animal model Type of cells Impact of morphine administration
onTumor progression
Reference
I.V. injection of tumor cells to
rats
MADB106 lung tumor cells Increase of lung diffusion of tumor cells in
the presence of surgical stress
Franchi et al. (2007)
S.C./I.P. injection of tumor
cells to mice
EL-4 leukemia
Sarcoma 180 carcinoma
P388 leukemia
Meth-A sarcoma
Increase in the weight of solid tumors and
increased mortality caused by ascite-type
tumors
Ishikawa et al. (1993)
Matrigel plugs and breast
xenografts in mice
MCF-7 breast cancer cell Increase in tumor size and angiogenesis Gupta et al. (2002)
I.V. injection of tumor cells to
mice
26-L5 colon carcinoma cells Decrease in the number of metastatic
colonies in lungs
Harimaya et al. (2002)
Tumor cell-containing matrigel
plugs in mice
Mouse Lewis lung carcinoma
cells
Reduction in tumor cell-induced angiogenesis Koodie et al. (2010)
S.C. tumor xenografts in mice Ehrlich ascites Inhibition of tumor growth via suppression of
tumor angiogenesis and increased tumor cell
apoptosis
Ustun et al. (2010)
I.V. inoculation of tumor cells
to rats
MADB106 breast cancer cells Inhibition of surgery-induced increase in
metastatic localization of tumor cells in lungs
Page et al. (1993, 1994, 1998)
I.V. injection of tumor cells to
rats by laparotomy
Colon adenocarcinoma cells Decrease in the incidence and burden of
metastatic tumors in the liver
Yeager and Colacchio (1991)
I.V. injection of tumor cells to
rats with laparotomy
Colon adenocarcinoma cells Increase in the incidence and burden of
metastatic tumors in the liver
Colacchio et al. (1994)
Tumor cell inoculation into
hind paw of mice
B16–BL6 melanoma cells Decrease in tumor growth and the number of
metastatic nodules in the lungs 2weeks
after tumor excision
Sasamura et al. (2002)
S.C. injection of tumor cells in
the right hind thigh
SCK mammary carcinoma
cells
Increase in tumor angiogenesis
Increase in tumor weight as well as
incidence and burden of lung metastases
Farooqui et al. (2007)
I.V. injection of tumor cells to
rats 4–5 h after induction of
anesthesia (morphine
administration) for laparotomy
MADB106 mammary
adenocarcinoma cells
Attenuation of surgery-induced surge in lung
retention of tumor cells 24 h after tumor cell
injection
No signiﬁcant effect on the number of
metastatic colonies in lungs after 3weeks
Bar-Yosef et al. (2001)
S.C. injection of tumor cells to
mice
MCF-7 and MDA-MB231
breast cancer cells
HT-29 colon cancer cells
Smaller volume of MCF-7 and MDA-MB231
tumors compared to control groups
No effect on the size of HT-29 tumors
Tegeder et al. (2003)
REGIONAL ANESTHESIA AND ANALGESIA
In animal models it has been demonstrated that epidural or spinal
blockade results in a reduction of the immune suppression after
surgery andprotection against postoperativemetastasis (Bar-Yosef
et al., 2001; Wada et al., 2007). Recent retrospective studies have
been conducted to unveil potential signiﬁcant differences in cancer
recurrence and or metastasis after surgery with regional or gen-
eral anesthesia. Two retrospective studies on breast and prostate
cancer showed that cancer recurrence rate was lower when gen-
eral anesthesia was supplemented with regional (i.e., epidural or
paravertebral) anesthesia. Exadaktylos et al. (2006) studied the
medical history of 129 patients that had undergone mastectomy
for primary breast cancer and found lower cancer recurrence and
metastasis ∼2.5 years after surgery in patients that received par-
avertebral anesthesia with general anesthesia compared to those
that had received general anesthesia alone (Exadaktylos et al.,
2006). Similarly Biki et al. (2008) showed that in radical prosta-
tectomy, using epidural anesthesia and analgesia was associated
with a lower risk of biochemical cancer recurrence, identiﬁed
as a postoperative increase in prostate-speciﬁc antigen (PSA),
in a follow-up period of 2.8–12.8 years (Biki et al., 2008). In a
partly supporting study, epidural anesthesia/analgesia comple-
mentary to general anesthesia was found to be associated with
a longer survival rate in patients with non-metastatic (but not
metastatic) colon cancer (Christopherson et al., 2008). However,
other retrospective studies failed to show any beneﬁts for regional
anesthesia/analgesia regarding recurrence and mortality rate after
surgery for prostate, colorectal, and cervical cancers even though
it reduced the need for postoperative systemic opioid administra-
tion (Gottschalk et al., 2010a; Ismail et al., 2010; Tsui et al., 2010).
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Clearly, and as acknowledged by the authors, retrospective studies
suffer from a high rate of selection and confounding biases. Fur-
thermore, these studies were designed to test different anesthesia
and analgesia regimens rather than the effect of morphine, and
the existence of multiple uncontrolled variables in the two groups
made it difﬁcult to attribute the observed results to morphine
administration as an independent factor.
Samples from patients given general anesthesia with regional
anesthesia/analgesia or opioid analgesia for cancer surgery have
also been investigated for pro- or anti-tumor effects in vitro. Serum
from patients of a prospective study, treated with a combina-
tion of general anesthesia with paravertebral anesthesia/analgesia,
increased the proliferation but not themigration of culturedMCF-
7 breast cancer cells when compared to general anesthesia and
opioid analgesia group (Deegan et al., 2009). Furthermore, the
postoperative serum concentration of pro-tumor cytokines, IL-1β
and IL-8, and of the pro-angiogenic factor VEGF-C were con-
siderably lower while anti-tumor cytokine, IL-8 was higher in
breast cancer surgerypatients treatedwithparavertebral anesthesia
and analgesia rather than general anesthesia and opioid analgesia
(Deegan et al., 2010; Looney et al., 2010).
The only prospective study with ﬁnalized and published results
testing the effect of anesthesia and pain management on cancer
recurrence and mortality is a multicenter randomized, controlled
clinical trial performed in Australia, New Zealand, and Asia. In
this study 503 patients undergoing major abdominal surgery for
cancer, mostly colon cancer, were randomly assigned to receive
general anesthesia with either epidural anesthesia and analgesia,
or postoperative intravenous opioid analgesia. The results showed
no signiﬁcant difference in cancer recurrence and mortality at 2–
3 years between the two groups (Myles et al., 2011), conﬁrming
the relative lack of effect seen with colon cancer in retrospec-
tive studies (Christopherson et al., 2008). The results of these
clinical studies are summarized in Table 2. Several randomized
controlled clinical trials are still in progress to assess the possible
effect of anesthetic technique on the course of cancer,which might
be tumor site-speciﬁc. These studies are following up the recur-
rence, metastasis, and mortality rates in patients randomized to
receive either general or regional anesthesia/analgesia for surgical
removal of different types of cancer in multiple clinical centers
(Gottschalk et al., 2010b; Afsharimani et al., 2011). Whether a
simple modiﬁcation of the anesthetic technique and postoper-
ative pain management can improve survival of cancer surgery
patients is a highly important question awaiting the results of
these prospective trials.
MU OPIOID RECEPTOR ANTAGONISTS
Considering thepossibility thatmorphinemight havedirect effects
on tumor growth, (as opposed to centrally ablating of the stress
response), the co-administration of a peripheral antagonist capa-
ble of reversing the unwanted peripheral effects of morphine
without affecting its central analgesic properties is an attractive
option.
This hypothesis has been tested in several experimental set-
tings. An in vitro study showed that pre-treatment of cul-
tured human endothelial cells with methylnaltrexone reversed
the proliferation- and migration-inducing effects of morphine
and other opioid agonists (Singleton et al., 2006). Furthermore,
in vitro and in vivo evidence were documented showing that
methylnaltrexone inhibits the disruption of endothelial cell barrier
and the increased vascular permeability induced by mu recep-
tor agonists, thrombin or lipopolysaccharide (Singleton et al.,
2007). As a result, methylnaltrexone was suggested to have poten-
tial therapeutic applications in controlling tumor angiogenesis.
Methylnaltrexone was further shown to have synergistic effects on
the anti-angiogenic effect of the anti-cancer drugs bevacizumab,5-
ﬂuorouracil, rapamycin, and temsirolimus (Singleton et al., 2008,
2010). Results also demonstrated the involvement of mu opi-
oid receptors in the proliferation and migration of lung cancer
cells. Naltrexone as well as MOR knockdown attenuated tumor
cell growth and invasion and prevented tumor growth and inva-
sion in vitro and metastasis in mice. Interestingly tumors did
not develop in MOR knockout mice to which lung tumor cells
where injected (Mathew et al., 2011). Moreover, the opioid antag-
onist naloxone decreased 17beta-estradiol-induced proliferation
of MCF-7 breast cancer cells by 65%, due to antagonism of either
Mu opioid or estrogen receptors (Farooqui et al., 2006). Currently,
a phase II clinical trial is recruiting subjects to study the possible
anti-tumor effects of naltrexone tablets, on estrogen-dependent
breast cancer (clinicaltrials.gov using the search words opioid
antagonist cancer). However, a retrospective clinical study of
patients undermethadonemaintenance therapy failed to show any
advantage of naltrexone compared to methadone in the formation
of new cancers (Singleton and Moss, 2010).
The potential use of opioid antagonists in the context of cancer
is debatable in viewof contrasting literature: naltrexonewas shown
to increase the proliferation of colon, pancreatic, and head and
neck cancer cells in vitro. This effect was suggested to be due to
antagonism of the growth inhibiting effect of endogenous opi-
oid [Met5]enkephalin (Zagon et al., 1996, 2000). Moreover, in a
chorioallantoic membrane assay, anti-angiogenic effects of up to
50% were observed for naltrexone (Blebea et al., 2000). Accord-
ingly, a study on angiogenesis during cholestasis in rats showed
naltrexone to promote angiogenesis in the liver tissue (Faramarzi
et al., 2009). Further studies, including randomized controlled
clinical trials, would shed light on whether peripheral opioid
antagonists improve cancer free survival when added to opioid
analgesia after cancer surgery.
ALTERNATIVE ANALGESIC INTERVENTIONS
Alternative pain-relieving drugs devoid of immunosuppressive
effect have beenproposed to replacemorphine in the postoperative
pain management of cancer surgery patients. These include other
opioids than morphine, non-steroidal anti-inﬂammatory drugs
(NSAIDs), and adrenergic-active drugs.
Fentanyl and its derivatives sufentanil and remifentanil are
highly lipophilic and potent mu receptor agonists, widely used in
anesthesia (Forget and De Kock, 2009). While some studies show
that these drugs lack the immunosuppressive effects of morphine
(Bilﬁnger et al., 1998;Yeager et al., 2002;Akural et al., 2004), several
lines of evidence denoted suppressed cellular immune function
and increased risk of metastasis with their perioperative admin-
istration (Beilin et al., 1996; Sacerdote et al., 2001; Shavit et al.,
2004). Partial agonists such as buprenorphine have been suggested
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Table 2 |The effect of perioperative anesthetic/analgesic technique on cancer recurrence and survival.
Type of study Surgical procedure Anesthetic/analgesic
regimen
Effect on the course
of cancer
Reference
Retrospective clinical
study
Mastectomy for primary
breast cancer
GA+PVA (n =50)
GA+PCA (n =79)
Lower cancer recurrence or
metastases in patients receiving
PVA+GA
Exadaktylos et al. (2006)
Retrospective clinical
study
Open radical
prostatectomy for invasive
prostate cancer
GA+EA (n =102)
GA+Opioid analgesia
(n =123)
Lower risk of biochemical cancer
recurrence in patients receiving
EA
Biki et al. (2008)
Retrospective clinical
study
Resection of colon cancer GA+ IV opioids (n =92)
GA+EA (n =85)
Higher survival rate in patients
with non-metastatic, but not
metastatic colon cancer
Christopherson et al. (2008)
Secondary analysis of
subjects of a
randomized controlled
clinical trial
Radical prostatectomy for
prostate cancer
GA+EA (n =49)
GA+ IV morphine (n =50)
No difference between the
group receiving epidural
anesthesia and control groups
Tsui et al. (2010)
Retrospective clinical
study
Colorectal cancer surgery GA+EA (n =256)
GA (n =253)
No difference in cancer
recurrence rate in normal
subjects
Lower cancer recurrence rate
with EA in subjects older than
64 year
Gottschalk et al. (2010a)
Retrospective clinical
study
Brachytherapy for cervical
cancer
Neuraxial anesthesia (SA/EA)
(n =63)
GA (n =69)
No difference in tumor
recurrence and mortality rate
between the two groups
Ismail et al. (2010)
Prospective,
randomized, controlled
clinical trial
Excision of cancer by
major abdominal surgery
such as esophagectomy,
gastrectomy, hepatectomy,
pancreatectomy,
colectomy, nephrectomy,
cystectomy, radical
hysterectomy, and open
prostatectomy
GA+EA (n =230)
GA+ IV opioids (n =216)
No difference in long-term
cancer recurrence and mortality
after major abdominal surgery
Myles et al. (2011)
Retrospective Clinical
study
Primary excision of
cutaneous melanoma
Local anesthesia (n =2185)
GA (n =2136)
Slightly increased risk of
mortality in patients receiving
general anesthesia compared to
local anesthesia
Schlagenhauff et al. (2000)
In vitro Mastectomy for breast
cancer patients
GA+PVA (n =15)
GA+opioid analgesia (n =15)
Reduced surgical stress
response with PVA
No difference in pro-angiogenic
factors VEGF and PGE2
O’Riain et al. (2005)
In vitro Breast cancer surgery Propofol/PVA (n =11)
GA+ opioid analgesia (n =11)
Serum from patients receiving
propofol/PVA inhibited
proliferation, but not migration,
of breast cancer cells in vitro
Deegan et al. (2009)
In vitro Primary breast cancer
surgery
Propofol/PVA (n =15)
GA+ opioid analgesia (n =17)
Propofol/PVA alters some but not
all cytokines and MMPs in favor
of resistance against cancer
progression and metastasis
Deegan et al. (2010)
In vitro Primary breast cancer
surgery
Propofol/PVA (n =20)
GA+ morphine analgesia
(n =20)
Decreased postoperative serum
concentrations of VEGF-C and
increasedTGF-β in patients
receiving propofol/PVA
Looney et al. (2010)
GA, general anesthesia; PVA, paravertebral anesthesia; PCA, patient-controlled analgesia; EA, epidural anesthesia, SA, spinal anesthesia.
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as a replacement for morphine and fentanyl, based on animal
data showing buprenorphine is devoid of immunosuppressive
effects and protects against surgery-induced increased metasta-
sis (Franchi et al., 2007). Tramadol is a low-afﬁnity mu opioid
receptor agonist with complementary central inhibition of sero-
tonin and noradrenaline reuptake (Leppert, 2009). Tramadol not
only improved immune function in animals (Sacerdote et al., 1999;
Tsai and Won, 2001) but also reduced postoperative immunosup-
pression in patients undergoing surgery for uterine carcinoma,
while providing analgesic efﬁcacy comparable to that of morphine
(Vickers and Paravicini, 1995; Stamer et al., 1997; Hopkins et al.,
1998; Sacerdote et al., 2000; Hadi et al., 2006).
Non-steroidal anti-inﬂammatory drugs administration has dif-
ferent side effects and considerably lower risk of tolerance than
morphine (Anonymous, 1991). NSAIDs with different modes
of administration have signiﬁcant opioid-sparing effects and
improve post-surgical pain in different types of surgery. In minor
and intermediate surgical procedures they could be considered as
alternatives to opioids (Cashman et al., 1985; Anonymous, 1991;
Murphy, 1993). NSAIDs further help to improve immune func-
tion and host defense against malignant cells (Forget et al., 2010).
In addition, because cyclooxygenases (COX) I and II, catalyze the
formation of prostaglandins, which are involved in tumor for-
mation, growth, angiogenesis and invasion, NSAIDs and COX
inhibitors, particularly COX-2 inhibitors, offer a potential ben-
eﬁt in cancer therapy (Méric et al., 2006). It was demonstrated
that adding celecoxib, a selective COX-2 inhibitor, to morphine,
reduces the morphine-induced increase in prostaglandin secre-
tion and angiogenesis, growth and metastasis of breast tumor in
rodents (Farooqui et al., 2007; Benish et al., 2008). In a murine
model of surgery-induced cellular immunosuppression, perioper-
ative administration of the injectable NSAID ketorolac protected,
while morphine decreased, the natural killer (NK) cell activity
after laparotomy (Colacchio et al., 1994). In a recent retrospective
analysis of breast cancer surgery patients, preoperative adminis-
tration of ketorolac was shown to be associated with lower cancer
recurrence while other drugs, namely sufentanil, ketamine, and
clonidine, failed to show such beneﬁcial effect (Forget et al., 2010).
Other strategies to assist in controlling postoperative pain and
reduce the need for opioid analgesics include systemic administra-
tion of glucocorticoids (Salerno andHermann,2006; Romundstad
and Stubhaug, 2007; Dahl et al., 2010), local inﬁltration of anes-
thetics such as lidocaine which was moderately and transiently
beneﬁcial in controlling acute pain after abdominal surgery (Dahl
et al., 2010), or beta blockers which via catecholamine inhibition
may enhance the immune function andprevent cancer progression
(Palm et al., 2006). Several studies have shown that intraoper-
ative infusion of beta blockers, and particularly the β1-blocker,
esmolol, decreases the intra- and post-operative use of opioids
(Johansen et al., 1998; White et al., 2003; Chia et al., 2004; Collard
et al., 2007). Moreover, beta blockers have synergistic effects with
COX-2 inhibitors, preserving the immune function after surgery,
and reducing the risk of postoperative metastasis in rats (Ben-
ish et al., 2008). However safety studies, particularly in patients
susceptible to risks associated with hypotension, are required
(Yu et al., 2011). Currently a randomized clinical trial is testing
the ability of intravenous esmolol to enhance postoperative pain
relief and reduce the need for intraoperative opioids in patients
undergoing laparoscopic prostatectomy and upper gastrointesti-
nal surgery (clinicaltrials.gov using the search words beta-blocker
cancer surgery).
Another intervention on the adrenergic system with possible
opioid-sparing effect would be α-2 adrenergic receptor activa-
tion. The antihypertensive drug clonidine is used preoperatively
to prolong regional anesthesia and reduces the need for systemic
anesthetics and postoperative opioid analgesics (Pyati and Gan,
2007). However due to its multiple side effects such as exces-
sive hypotension, sedation, and bradycardia its use is limited to
regional administration (Buvanendran and Kroin, 2009). More-
over, clonidine and dexmedetomidine, another α2-agonist used
in the intensive care unit, were shown to enhance breast tumor
growth in a mouse model, possibly via enhanced breast tumor cell
proliferation and apoptosis inhibition (Bruzzone et al., 2008).
The anti-convulsant drug gabapentin has also been proposed to
reduce acute postoperative pain and the need for opioid adminis-
tration. This beneﬁcial effect of gabapentin has been conﬁrmed
by several randomized controlled clinical trials in oncological
and non-oncological surgeries (Eckhardt et al., 2000; Dirks et al.,
2002; Fassoulaki et al., 2002; Mathiesen et al., 2007). Pregabalin,
another derivative of this family has also been suggested to have
opioid-sparing effects, however the results of clinical trials on its
dose-dependent efﬁcacy are inconsistent and its use in periopera-
tive pain management still questionable (Dahl et al., 2010). While
these drugs are proven to alleviate pain immediately after surgery,
the long-term outcome of their administration is unknown (Tiip-
pana et al., 2007). Moreover, although they signiﬁcantly reduce
the postoperative side effects of opioids such as nausea, vomiting,
and urinary retention, they aggravate sedation to a great extent
(Tiippana et al., 2007; Dahl et al., 2010).
In conclusion, laboratory data available at the moment do
not draw a clear picture of morphine as a tumor-promoting
or inhibiting agent. The ﬁrst prospective trial testing whether
regional anesthesia and analgesia improved cancer recurrence and
metastasis has not conﬁrmed the promising conclusions drawn
from retrospective studies, however further prospective trials are
still ongoing as the effect may be cancer type speciﬁc. Even if
these prospective trials were to show a beneﬁt to cancer patients
in using regional analgesia and anesthesia and reduced opioid
postoperative analgesia, the role of opioids per se would not be
demonstrated.
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